Blood test may flag hidden kidney disease risk before damage is done
NCT ID NCT06839833
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This study tests a blood-based genetic test designed to identify people who carry two copies of high-risk APOL1 gene variants, which are linked to a type of kidney disease. Around 2,000 participants who are already being considered for a separate treatment trial will provide a blood sample for the test. The goal is to see if the test can reliably find those who might be eligible for a new experimental therapy targeting APOL1-mediated kidney disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- APOL1 genotyping test (a diagnostic blood test to detect high-risk APOL1 gene variants)
- What this could lead to
- If the test works well, it could help identify people who may benefit from a new targeted therapy for APOL1-related kidney disease.
- What could go wrong
- This is an early-stage diagnostic study, not a treatment trial. The test may not be accurate enough in real-world use, and even if it is, the linked treatment is still being tested.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for APOL1-MEDIATED KIDNEY DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Almac Diagnostic Services LLC
RECRUITINGDurham, North Carolina, 27704, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.